Focus, or Focus 580, was WILL Radio's flagship talk program from 1981 until 2014. David Inge was the host from 1981 until his retirement in 2012. Always engaging, the program acted as a resource for citizens to directly question politicians and candidates as well as keep up on the arts, science, health, and even the latest from well-known novelists.
The Focus archive below offers thousands of great interviews and serves as a time capsule and a great resource for researchers and those just curious about how influential people spoke of important topics as they were happening.
There’s been a steady flow of industry and people out of some downstate Illinois factory towns for years. This hour on Focus, we'll look at the numbers and hear from one town that has stopped the outflow of people, even after their Maytag plant relocated.
Talking about mental health and mental illness is hard; sometimes it awkward. Most of the time it’s uncomfortable. Should it be?
During this Focus interview, Jeff Bossert talks with Steve James and Chaz Ebert about capturing the life of a critic on film.
As a part of our series, "Unmet Needs: living with mental illness in central Illinois," we convened what we hope is the first of many Twitterchats. Here's a recap.
In many places in Illinois, providers are looking to telemedicine to expand access to psychiatric care. Friday on Focus, we take a look at the nuances of treating patients via a computer screen as a part of our series “Unmet Needs: Living with mental illness in central Illinois.”
Friday, April 11 at 11:00 a.m. central time, Lindsey Mooon @lindseysmoon will be hosting a Twitterchat with reporter Sean Powers @SeanCPow at the hashtag #WILLchat to talk about mental illness and the associated stigmas that exist in Illinois.
Thousands of soldiers who’ve served in the military in the last decade in Iraq and Afghanistan are using the G.I. Bill to finish a college degree, but it’s not easy.
The science behind medical marijuana is hazy, in part because it's difficult for scientists to gain access to the drug for research.
